Skip to content Skip to footer

YIV-906: Therapeutics—first-in-class botanical cancer platform drug

Ongoing since 2020 Company Overview Innovation: Therapeutics—first-in-class botanical cancer platform drug Targeted Cancer(s): Liver cancer Scientific Leadership: Yung-Chi Cheng, Ph.D.; Shwu-Huey Liu, Ph.D. Stage of Project: Phase II clinical trial about to commence; orphan drug designations granted by the U.S. Food and Drug Administration (FDA) Opportunity YIV-906 is a botanical cancer drug that…

Read More